Literature DB >> 26449659

Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.

B Bilori1, S Thota2, M J Clemente2, B Patel2, A Jerez3, M Afable Ii2, J P Maciejewski2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26449659     DOI： 10.1038/leu.2015.280

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  Somatic STAT3 mutations in large granular lymphocytic leukemia.

Authors:  Hanna L M Koskela; Samuli Eldfors; Pekka Ellonen; Arjan J van Adrichem; Heikki Kuusanmäki; Emma I Andersson; Sonja Lagström; Michael J Clemente; Thomas Olson; Sari E Jalkanen; Muntasir Mamun Majumder; Henrikki Almusa; Henrik Edgren; Maija Lepistö; Pirkko Mattila; Kathryn Guinta; Pirjo Koistinen; Taru Kuittinen; Kati Penttinen; Alun Parsons; Jonathan Knowles; Janna Saarela; Krister Wennerberg; Olli Kallioniemi; Kimmo Porkka; Thomas P Loughran; Caroline A Heckman; Jaroslaw P Maciejewski; Satu Mustjoki
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

Review 3.  Therapeutic targeting of Janus kinases.

Authors:  Marko Pesu; Arian Laurence; Nandini Kishore; Samuel H Zwillich; Gary Chan; John J O'Shea
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

4.  FDA approves tofacitinib for rheumatoid arthritis.

Authors:  Kate Traynor
Journal:  Am J Health Syst Pharm       Date:  2012-12-15       Impact factor: 2.637

Review 5.  Autoimmune manifestations in large granular lymphocyte leukemia.

Authors:  Bruno Bockorny; Constantin A Dasanu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-09-19

6.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 7.  Cytokine receptor signal transduction and the control of hematopoietic cell development.

Authors:  S S Watowich; H Wu; M Socolovsky; U Klingmuller; S N Constantinescu; H F Lodish
Journal:  Annu Rev Cell Dev Biol       Date:  1996       Impact factor: 13.827

Review 8.  The spectrum of large granular lymphocyte leukemia and Felty's syndrome.

Authors:  Xin Liu; Thomas P Loughran
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

9.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

Authors:  P K Epling-Burnette; J H Liu; R Catlett-Falcone; J Turkson; M Oshiro; R Kothapalli; Y Li; J M Wang; H F Yang-Yen; J Karras; R Jove; T P Loughran
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

10.  Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.

Authors:  Sanjay R Mohan; Michael J Clemente; Manuel Afable; Heather N Cazzolli; Nelli Bejanyan; Marcin W Wlodarski; Alan E Lichtin; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941
View more
  23 in total

Review 1.  A Practical Guide to the Safety and Monitoring of New IBD Therapies.

Authors:  Benjamin Click; Miguel Regueiro
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

Review 2.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Authors:  Thomas A Waldmann; Jing Chen
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

3.  T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib).

Authors:  Geling Li; Emily Waite; Julie Wolfson
Journal:  Blood Adv       Date:  2017-12-18

4.  Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia.

Authors:  Tyler G Ketterl; David Wu; Jonathan R Fromm; Lorinda Soma; Ann E Dahlberg; Brent L Wood; Katherine Tarlock
Journal:  Bone Marrow Transplant       Date:  2017-12-21       Impact factor: 5.483

Review 5.  Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease.

Authors:  Nina Couette; Wael Jarjour; Jonathan E Brammer; Alexa Simon Meara
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

6.  Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.

Authors:  Kristine C Olson; Paige M Kulling Larkin; Rossana Signorelli; Cait E Hamele; Thomas L Olson; Mark R Conaway; David J Feith; Thomas P Loughran
Journal:  Cytokine       Date:  2018-11-17       Impact factor: 3.861

7.  Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.

Authors:  Cédric Pastoret; Fabienne Desmots; Gaëlle Drillet; Simon Le Gallou; Marie-Laure Boulland; Alexia Thannberger; Anne-Violaine Doncker; Véronique Salaun; Gandhi Laurent Damaj; Richard Veyrat-Masson; Olivier Tournilhac; Aline Moignet; Céline Pangault; Mikaël Roussel; Thierry Fest; Thierry Lamy
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

Review 8.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

9.  Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias.

Authors:  Linus Wahnschaffe; Marco Herling
Journal:  Hemasphere       Date:  2021-06-01

10.  Process Pharmacology: A Pharmacological Data Science Approach to Drug Development and Therapy.

Authors:  Jörn Lötsch; Alfred Ultsch
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.